What role does CYP2C19 play in Wechseljahre?

CYP2C19 is a key drug-metabolizing enzyme primarily expressed in the liver. It does not play a direct regulatory role in menopause (Wechseljahre) itself, but it becomes indirectly relevant because many women during this life stage take medications that are metabolized by CYP2C19 – such as certain antidepressants (e.g., citalopram, escitalopram), proton pump inhibitors (omeprazole), or the antiestrogen tamoxifen. Genetic variants in CYP2C19 (e.g., *2, *3, *17) determine whether an individual is a normal, intermediate, poor, or ultrarapid metabolizer. This can affect the efficacy and side-effect risk of these drugs. For example, poor metabolizers often require lower doses of antidepressants, while ultrarapid metabolizers may not achieve sufficient drug levels. However, there is no strong evidence that CYP2C19 variants directly cause or alleviate hot flashes, mood swings, or other menopausal symptoms. The relevance lies mainly in personalized medication management during menopause. Caveat: direct-to-consumer genetic tests may miss rare variants; clinical confirmation and physician consultation are essential before any medication changes.